MedTrace Logo

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

NCT07418749 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 398

Last updated 2026-04-06

No results posted yet for this study

Summary

The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.

Conditions

  • Recurrent Cervical Cancer
  • Metastatic Cervical Cancer

Interventions

DRUG

SHR-A2102 for Injection

SHR-A2102 for injection.

DRUG

Pemetrexed Disodium for Injection

Pemetrexed Disodium for injection.

DRUG

Gemcitabine Hydrochloride for Injection

Gemcitabine Hydrochloride for injection.

DRUG

Topotecan Hydrochloride for Injection

Topotecan Hydrochloride for injection.

DRUG

Paclitaxel for Injection (Albumin bound)

Paclitaxel for injection (Albumin bound).

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-30
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07418749 on ClinicalTrials.gov